SG11202004863QA - Zika vaccines and immunogenic compositions, and methods of using the same - Google Patents
Zika vaccines and immunogenic compositions, and methods of using the sameInfo
- Publication number
- SG11202004863QA SG11202004863QA SG11202004863QA SG11202004863QA SG11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- same
- immunogenic compositions
- zika vaccines
- zika
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/22—Testing for sterility conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592995P | 2017-11-30 | 2017-11-30 | |
| PCT/US2018/059227 WO2019090233A2 (en) | 2017-11-03 | 2018-11-05 | Method for inactivating zika virus and for determining the completeness of inactivation |
| PCT/US2018/059233 WO2019090238A1 (en) | 2017-11-03 | 2018-11-05 | Zika vaccines and immunogenic compositions, and methods of using the same |
| PCT/US2018/063369 WO2019108970A1 (en) | 2017-11-30 | 2018-11-30 | Zika vaccines and immunogenic compositions, and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004863QA true SG11202004863QA (en) | 2020-06-29 |
Family
ID=66664221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004863QA SG11202004863QA (en) | 2017-11-30 | 2018-11-30 | Zika vaccines and immunogenic compositions, and methods of using the same |
| SG11202003975WA SG11202003975WA (en) | 2017-11-30 | 2018-11-30 | Method for inactivating zika virus and related methods |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003975WA SG11202003975WA (en) | 2017-11-30 | 2018-11-30 | Method for inactivating zika virus and related methods |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20210403879A1 (https=) |
| EP (2) | EP3717511A4 (https=) |
| JP (4) | JP2021505549A (https=) |
| KR (2) | KR20200094191A (https=) |
| CN (4) | CN111527104A (https=) |
| AU (5) | AU2018375789B2 (https=) |
| BR (2) | BR112020010466A2 (https=) |
| CA (2) | CA3084605A1 (https=) |
| MX (2) | MX2020005554A (https=) |
| SG (2) | SG11202004863QA (https=) |
| WO (2) | WO2019108976A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200117981A (ko) | 2017-11-03 | 2020-10-14 | 다케다 백신즈 인코포레이티드 | 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들 |
| MX2020005554A (es) | 2017-11-30 | 2020-10-12 | Takeda Vaccines Inc | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. |
| WO2020017765A1 (ko) * | 2018-07-18 | 2020-01-23 | (주)진매트릭스 | 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물 |
| BR112021019845A2 (pt) * | 2019-05-08 | 2022-02-15 | Takeda Vaccines Inc | Composições de vírus inativado e formulações de vacina contra zika |
| RU2717993C1 (ru) * | 2019-10-22 | 2020-03-27 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Способ получения антигена вируса Зика, обладающего иммуногенными и антигенными свойствами |
| EP4476329A1 (en) | 2022-02-09 | 2024-12-18 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| CN121263205A (zh) * | 2023-02-06 | 2026-01-02 | 塞维卡有限责任公司 | 修饰的piv5疫苗载体：制造方法和用途 |
| CN121221758B (zh) * | 2025-12-02 | 2026-03-03 | 华诺泰生物医药科技(成都)有限公司 | 一种即用型稳定3d-mla佐剂溶液的制备方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT405939B (de) * | 1997-02-24 | 1999-12-27 | Immuno Ag | Verfahren zur inaktivierung von lipidumhüllten viren |
| DK1025209T3 (da) | 1997-08-28 | 2007-06-25 | Cheil Jedang Corp | Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine |
| GB0326439D0 (en) * | 2003-11-13 | 2003-12-17 | Imp College Innovations Ltd | Methods |
| RS20070078A (sr) | 2004-08-27 | 2008-11-28 | Panacea Biotec Ltd., | Inaktivirana vakcina protiv poliomijelitisa nastala iz sabinovog soja polio virusa |
| EP1724338A1 (en) | 2005-05-19 | 2006-11-22 | Crucell Holland B.V. | Methods for the production of a whole-inactivated West Nile Virus vaccine |
| CN101516395B (zh) | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| CN107375919B (zh) | 2009-03-27 | 2022-07-29 | 台湾地区“中央研究院” | 抗病毒免疫的方法和组合物 |
| CN101954076A (zh) | 2009-04-27 | 2011-01-26 | 免疫制剂美国公司 | 自身免疫性肝炎的免疫疗法和预防 |
| CN101876650B (zh) | 2010-07-02 | 2014-04-09 | 中国烟草总公司郑州烟草研究院 | 一种烟用水基胶中甲醛含量的测定方法 |
| EP2714076A1 (en) | 2011-05-26 | 2014-04-09 | GlaxoSmithKline Biologicals S.A. | Inactivated dengue virus vaccine |
| EP2720715B1 (en) | 2011-06-17 | 2017-08-09 | Bharat Biotech International Limited | Vaccine composition comprising an inactivated chikungunya virus strain |
| EP3269386B1 (en) | 2011-12-06 | 2022-09-14 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
| US10598666B2 (en) | 2012-03-08 | 2020-03-24 | Glaxosmithkline Biologicals Sa | In vitro potency assay for protein-based meningococcal vaccines |
| EP2822584A1 (en) | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
| US9895437B2 (en) | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
| CN102680595A (zh) | 2012-05-03 | 2012-09-19 | 安阳市双环助剂有限责任公司 | 分散剂mf中游离甲醛含量的测定方法 |
| WO2015059714A1 (en) | 2013-09-14 | 2015-04-30 | Bharat Biotech International Limited | Emergency mode in a hybrid vehicle |
| SG11201702116VA (en) | 2014-09-17 | 2017-04-27 | Univ Iowa Res Found | Viral rna segments as immunomodulatory agents and vaccine components |
| UA125788C2 (uk) | 2014-10-07 | 2022-06-08 | Серум Інстітют Оф Індія Прайвт Лімітед | Спосіб інактивації ентеровірусу, ад'ювант адсорбції та композиція із зменшеною дозою вакцини, одержана з ним |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| US10086061B2 (en) | 2015-03-11 | 2018-10-02 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
| BR112017027770A2 (pt) | 2015-06-22 | 2018-09-11 | Harvard College | composições e métodos para modular infecção viral |
| EP3322441A4 (en) * | 2015-07-16 | 2018-12-19 | Bharat Biotech International Limited | Vaccine compositions |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11111481B2 (en) | 2015-09-30 | 2021-09-07 | Ramot At Tel-Aviv University Ltd. | Attenuated virus mutated at sites of evolutionarily conserved RNA structure |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| ES2973267T3 (es) | 2015-12-23 | 2024-06-19 | Valneva Se | Purificación de virus |
| EP3184119A1 (en) | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| US11434259B2 (en) | 2016-01-25 | 2022-09-06 | Iogenetics, Llc | Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity |
| SG10201913630YA (en) | 2016-02-17 | 2020-03-30 | Curevac Ag | Zika virus vaccine |
| AU2017222644B2 (en) | 2016-02-25 | 2021-07-29 | The Trustees Of The University Of Pennsylvania | Novel vaccines against Zika virus |
| WO2017161151A1 (en) | 2016-03-16 | 2017-09-21 | Novavax, Inc. | Vaccine compositions containing modified zika virus antigens |
| CN105749268B (zh) * | 2016-04-11 | 2020-09-11 | 北京科兴中维生物技术有限公司 | 一种灭活的寨卡病毒疫苗 |
| US20170298119A1 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| WO2017192856A1 (en) | 2016-05-04 | 2017-11-09 | University Of Miami | Zika virus vector for treating zika virus infection |
| WO2017197034A1 (en) | 2016-05-10 | 2017-11-16 | Najit Technologies, Inc. | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production |
| US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
| BE1024796B9 (fr) | 2016-06-02 | 2019-01-08 | Glaxosmithkline Biologicals Sa | Constructions antigeniques du virus zika |
| BR112018075440A2 (pt) | 2016-06-09 | 2019-04-02 | Beth Israel Deaconess Medical Center | composições e métodos para prevenir e tratar a infecção por zika vírus |
| GB201610162D0 (en) | 2016-06-10 | 2016-07-27 | Imp Innovations Ltd And Inst Pasteur | Methods |
| US10947277B2 (en) | 2016-06-13 | 2021-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays |
| BR112018077041A2 (pt) | 2016-07-08 | 2019-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale | sequências genômicas que codificam para um vírus da zika mutante atuado |
| WO2018009603A1 (en) | 2016-07-08 | 2018-01-11 | The United State of America, as represented by the Secretary, Department of Health and Human Service | Chimeric west nile/zika viruses and methods of use |
| WO2018022786A1 (en) | 2016-07-26 | 2018-02-01 | Washington University | Antibodies to zika virus and methods of use thereof |
| GB201613191D0 (en) | 2016-07-29 | 2016-09-14 | Univ Oxford Innovation Ltd | Zika virus vaccine |
| WO2018091540A1 (en) | 2016-11-17 | 2018-05-24 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| US20190358313A1 (en) | 2016-12-23 | 2019-11-28 | Expres2Ion Biotechnologies Aps | New flavivirus vaccine |
| CN108503697B (zh) | 2017-02-27 | 2023-03-31 | 中国科学院上海巴斯德研究所 | 一种果蝇细胞表达的寨卡病毒亚单位疫苗 |
| CN108503696B (zh) | 2017-02-27 | 2023-05-12 | 中国科学院上海巴斯德研究所 | 一种酵母细胞表达的寨卡病毒亚单位疫苗 |
| WO2018165373A1 (en) | 2017-03-08 | 2018-09-13 | University Of Georgia Research Foundation, Inc. | Methods and compositions related to increased viral production |
| US11370830B2 (en) | 2017-04-07 | 2022-06-28 | The Rockefeller University | Neutralizing antibodies that bind to the zika virus domain III envelope region |
| WO2018237039A1 (en) | 2017-06-20 | 2018-12-27 | Texas Tech University System | Zika virus like particle (vlp) based vaccine and microneutralization assay |
| EP3417943B1 (de) * | 2017-06-21 | 2020-02-12 | Eppendorf AG | Zentrifugenrotor mit abdichtung |
| CN107188935B (zh) | 2017-07-20 | 2018-10-02 | 北京健乃喜生物技术有限公司 | 一种寨卡病毒ns1抗原突变体及其应用 |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| CN107537029B (zh) | 2017-09-14 | 2021-03-19 | 北京科兴生物制品有限公司 | 一种寨卡病毒与黄热病毒联合灭活疫苗 |
| GB201716254D0 (en) | 2017-10-05 | 2017-11-22 | Univ Leuven Kath | Live-attenuated flaviruses with heterologous antigens |
| KR20200117981A (ko) | 2017-11-03 | 2020-10-14 | 다케다 백신즈 인코포레이티드 | 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들 |
| WO2019104157A1 (en) | 2017-11-21 | 2019-05-31 | The University Of Vermont And State Agricultural College | Highly specific zika neutralizing human antibodies |
| MX2020005554A (es) | 2017-11-30 | 2020-10-12 | Takeda Vaccines Inc | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. |
| CN108187036A (zh) | 2017-12-08 | 2018-06-22 | 北京科兴中维生物技术有限公司 | 一种寨卡病毒与乙脑病毒联合灭活疫苗 |
| CN108210921A (zh) | 2017-12-29 | 2018-06-29 | 广州恩宝生物医药科技有限公司 | 一种寨卡病毒疫苗及其制备方法 |
| EP3755818A1 (en) | 2018-02-22 | 2020-12-30 | Nano4 Global, Lda | Method for detecting flaviviridae |
| WO2019172982A1 (en) | 2018-03-08 | 2019-09-12 | Codagenix Inc. | Attenuated flaviviruses |
| SG11202009147UA (en) | 2018-03-29 | 2020-10-29 | Emergex Vaccines Holding Ltd | Vaccine compositions |
| KR102075581B1 (ko) | 2018-04-27 | 2020-02-10 | 가톨릭대학교 산학협력단 | 바이러스성 발현 조절 서열이 삽입된 핵산 분자를 포함하는 면역보강제 및 이를 포함하는 약학 조성물 |
| WO2020017765A1 (ko) | 2018-07-18 | 2020-01-23 | (주)진매트릭스 | 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물 |
| CN111315407B (zh) | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
| US12064476B2 (en) | 2018-10-26 | 2024-08-20 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
| WO2020106358A1 (en) | 2018-11-20 | 2020-05-28 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| BR112021019845A2 (pt) | 2019-05-08 | 2022-02-15 | Takeda Vaccines Inc | Composições de vírus inativado e formulações de vacina contra zika |
| WO2021262659A1 (en) | 2020-06-22 | 2021-12-30 | University Of Connecticut | Flavivirus signal peptides, vaccine constructs, and methods therefor |
-
2018
- 2018-11-30 MX MX2020005554A patent/MX2020005554A/es unknown
- 2018-11-30 CA CA3084605A patent/CA3084605A1/en active Pending
- 2018-11-30 AU AU2018375789A patent/AU2018375789B2/en active Active
- 2018-11-30 AU AU2018375173A patent/AU2018375173B2/en active Active
- 2018-11-30 CA CA3085016A patent/CA3085016A1/en active Pending
- 2018-11-30 KR KR1020207018825A patent/KR20200094191A/ko not_active Ceased
- 2018-11-30 JP JP2020529448A patent/JP2021505549A/ja active Pending
- 2018-11-30 BR BR112020010466-3A patent/BR112020010466A2/pt not_active Application Discontinuation
- 2018-11-30 BR BR112020009960-0A patent/BR112020009960A2/pt unknown
- 2018-11-30 CN CN201880076318.4A patent/CN111527104A/zh active Pending
- 2018-11-30 MX MX2020004633A patent/MX2020004633A/es unknown
- 2018-11-30 JP JP2020529606A patent/JP7443233B2/ja active Active
- 2018-11-30 US US16/768,550 patent/US20210403879A1/en not_active Abandoned
- 2018-11-30 SG SG11202004863QA patent/SG11202004863QA/en unknown
- 2018-11-30 EP EP18884352.8A patent/EP3717511A4/en active Pending
- 2018-11-30 KR KR1020207018824A patent/KR20200090893A/ko not_active Ceased
- 2018-11-30 CN CN202310857430.4A patent/CN116983398A/zh active Pending
- 2018-11-30 CN CN201880076731.0A patent/CN111601885B/zh active Active
- 2018-11-30 US US16/768,499 patent/US11975062B2/en active Active
- 2018-11-30 CN CN202310861491.8A patent/CN116983399A/zh active Pending
- 2018-11-30 EP EP18883849.4A patent/EP3717638A4/en active Pending
- 2018-11-30 WO PCT/US2018/063381 patent/WO2019108976A1/en not_active Ceased
- 2018-11-30 WO PCT/US2018/063369 patent/WO2019108970A1/en not_active Ceased
- 2018-11-30 SG SG11202003975WA patent/SG11202003975WA/en unknown
-
2022
- 2022-01-19 AU AU2022200351A patent/AU2022200351B2/en active Active
- 2022-09-21 AU AU2022235577A patent/AU2022235577A1/en not_active Abandoned
- 2022-11-25 AU AU2022275515A patent/AU2022275515B2/en active Active
-
2023
- 2023-06-22 US US18/339,553 patent/US20240024454A1/en not_active Abandoned
- 2023-07-12 JP JP2023114640A patent/JP2023134630A/ja active Pending
- 2023-09-05 US US18/242,025 patent/US20240285747A1/en not_active Abandoned
- 2023-10-05 JP JP2023173547A patent/JP2024001177A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202003800YA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| IL275055A (en) | Tertiary antibody, method for its preparation and use | |
| IL257800A (en) | Immune compositions with improved stability and immunogenicity | |
| SG11202004863QA (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| IL268168A (en) | Immunogenic preparations for use as a vaccine against pneumococcus | |
| ZA202000889B (en) | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof | |
| ZA201603925B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| EP3119424A4 (en) | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof | |
| ZA201901032B (en) | Immunogenic/therapeutic glycan compositions and uses thereof | |
| GB201711635D0 (en) | Immunogenic composition | |
| EP3518955A4 (en) | TERT-IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT THEREOF | |
| IL269590A (en) | Methods and compositions for reducing immunogenicity | |
| IL251120A0 (en) | Immunogenic/therapeutic glycoside preparations and their uses | |
| IL271603A (en) | Immunogenic preparations | |
| SG11201803581VA (en) | Chimeric RSV, Immunogenic Compositions, and Methods of Use | |
| GB201721582D0 (en) | S aureus antigens and immunogenic compositions | |
| GB201801566D0 (en) | Methods and compositions for nanormulsion vaccine formulations | |
| GB201711637D0 (en) | Immunogenic composition | |
| EP3703745A4 (en) | IMMUNOGENIC CONJUGATES AND METHOD OF USING THEREOF | |
| IL258700A (en) | An excipient and a vaccine that includes it | |
| GB2570806B (en) | Immunogenic agent and associated compositions, uses and methods | |
| PL3615005T3 (pl) | Kompozycje i sposoby dostarczania szczepionki | |
| HK40030428A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| HK40031534A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| HK40030429A (en) | Zika vaccines and immunogenic compositions, and methods of using the same |